SCHEMBL1900513

SCHEMBL1900513

O=C(Nc1nnc(-c2ccco2)o1)c1cc(-c2ccccc2)nc2ccc(Br)cc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 9/20 0.81
KDM4E B2RXH2 4/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
TDP1 Q9NUW8 3/20 0.59
RXFP1 Q9HBX9 3/20 0.59
HPGD P15428 3/20 0.59
MAPT P10636 3/20 0.59
PPARG P37231 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
NCOR2 Q9Y618 2/20 0.59
ALDH1A1 P00352 2/20 0.59
ESR1 P03372 1/20 0.59
PLA2G1B P04054 1/20 0.59
POLB P06746 1/20 0.59
ALOX15 P16050 1/20 0.59
RECQL P46063 1/20 0.59
GFER P55789 1/20 0.59
ESR2 Q92731 1/20 0.59
HSD17B10 Q99714 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1899382 0.94 STAT3 (0.82) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL1905449 0.91 STAT3 (0.84) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL1900395 0.90 STAT3 (0.82) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL1899809 0.89 STAT3 (1.00) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL29382140 0.89 STAT3 (1.00) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL1896601 0.89 STAT3 (0.81) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL1898201 0.89 STAT3 (0.81) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL1897448 0.89 STAT3 (0.81) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL1904300 0.89 STAT3 (0.81) STAT3KDM4EMEN1KMT2ATDP1
SCHEMBL1901943 0.87 STAT3 (0.78) STAT3KDM4EMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885KDM4E 532/4885MEN1 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.